Gilead Sciences CEO John Milligan said the company did not anticipate the surge in patients who would be treated for hepatitis C after the introduction of Sovaldi and the impact on payers because of the drug’s high price. “I think our failure, if I have to take a step backwards, we were unable to have a good enough conversation with the payers,” Milligan said.